Lin F - Search Results

1

Deletion of either CD55 or CD97 ameliorates arthritis in mouse models.

Hoek RM, de Launay D, Kop EN, Yilmaz-Elis AS, Lin F, Reedquist KA, Verbeek JS, Medof ME, Tak PP, Hamann J. Hoek RM, et al. Among authors: lin f. Arthritis Rheum. 2010 Apr;62(4):1036-42. doi: 10.1002/art.27347. Arthritis Rheum. 2010. PMID: 20131275 Free article.

2

Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis.

Lin F, Emancipator SN, Salant DJ, Medof ME. Lin F, et al. Lab Invest. 2002 May;82(5):563-9. doi: 10.1038/labinvest.3780451. Lab Invest. 2002. PMID: 12003997 Free article.

3

Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.

Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. Lin F, et al. J Clin Invest. 2002 Nov;110(9):1269-74. doi: 10.1172/JCI16086. J Clin Invest. 2002. PMID: 12417565 Free PMC article.

4

Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.

Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME. Kaminski HJ, et al. Among authors: lin f. Exp Neurol. 2004 Oct;189(2):333-42. doi: 10.1016/j.expneurol.2004.06.005. Exp Neurol. 2004. PMID: 15380483

5

Bulk production and functional analyses of mouse CD55's native and deglycosylated active domains.

Lin F, Immormino RM, Shoham M, Medof ME. Lin F, et al. Arch Biochem Biophys. 2001 Sep 1;393(1):67-72. doi: 10.1006/abbi.2001.2488. Arch Biochem Biophys. 2001. PMID: 11516162

6

Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.

Kaminski HJ, Kusner LL, Richmonds C, Medof ME, Lin F. Kaminski HJ, et al. Among authors: lin f. Exp Neurol. 2006 Dec;202(2):287-93. doi: 10.1016/j.expneurol.2006.06.003. Epub 2006 Jul 20. Exp Neurol. 2006. PMID: 16859686

7

Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease.

Lin F, Spencer D, Hatala DA, Levine AD, Medof ME. Lin F, et al. J Immunol. 2004 Mar 15;172(6):3836-41. doi: 10.4049/jimmunol.172.6.3836. J Immunol. 2004. PMID: 15004190

8

Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.

Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Lalli PN, et al. Among authors: lin f. J Immunol. 2007 Nov 1;179(9):5793-802. doi: 10.4049/jimmunol.179.9.5793. J Immunol. 2007. PMID: 17947652 Free PMC article.

9

Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis.

Lin F, Salant DJ, Meyerson H, Emancipator S, Morgan BP, Medof ME. Lin F, et al. J Immunol. 2004 Feb 15;172(4):2636-42. doi: 10.4049/jimmunol.172.4.2636. J Immunol. 2004. PMID: 14764738

10

The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation.

O'Brien DP, Israel DA, Krishna U, Romero-Gallo J, Nedrud J, Medof ME, Lin F, Redline R, Lublin DM, Nowicki BJ, Franco AT, Ogden S, Williams AD, Polk DB, Peek RM Jr. O'Brien DP, et al. Among authors: lin f. J Biol Chem. 2006 May 12;281(19):13317-13323. doi: 10.1074/jbc.M601805200. Epub 2006 Mar 16. J Biol Chem. 2006. PMID: 16543227 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,451 results

Search Page